AH股脑机接口概念齐涨，机构称该技术正快速走向商业化应用

Core Insights - China has successfully conducted its first prospective clinical trial of an invasive brain-computer interface (BCI), marking the country as the second globally to enter the clinical trial phase for this technology [1][3]. Industry Developments - The clinical trial was a collaboration between the Chinese Academy of Sciences' Center for Excellence in Brain Science and Intelligent Technology, Fudan University Huashan Hospital, and relevant enterprises [3]. - The trial involved a male subject who lost his limbs due to a high-voltage accident. Since the implantation of the BCI device in March 2025, the system has operated stably, allowing the subject to perform tasks like playing chess and racing games after 2-3 weeks of training [3]. - The BCI technology aims to improve the quality of life for patients with spinal cord injuries and amputations through motor function replacement technology [3]. Market Response - Following the announcement, stocks related to brain-computer interface technology saw significant increases, with companies like Beiyikang and Aipeng Medical reaching 30% and 20% gains, respectively [1][2]. - The Hong Kong stock market also showed strong performance in BCI-related stocks, with Nanjing Panda Electronics rising over 40% [1]. Regulatory Environment - Multiple government departments, including the National Medical Products Administration and the National Healthcare Security Administration, have introduced policies to encourage the development of BCI technology and accelerate clinical applications [3]. - In February, the National Medical Products Administration approved a project to revise industry standards for medical devices using BCI technology [3]. Future Outlook - According to Shanghai Securities research, the BCI technology is rapidly transitioning from laboratory to commercial application, indicating significant growth potential in the Chinese market [4]. - The BCI industry is suitable for medium to long-term investment, with a focus on technology stability, mass production capabilities, and monitoring of research and product development [4].